Hot Investor Mandate 2: European PE Fund Invests Opportunistically in Drugs and Devices

27 Apr

A private equity firm based in Paris, France has a venture team that currently has €400M AUM. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of up to €2-3M, and up to €8M over the life of the investment, which can be start as early as seed stage. The firm preferably invests in European-based companies, and seeks to make about 2 allocations every year in the life sciences area (minority stakes).

The firm remains opportunistic in the life sciences, with a focus on drug development and medical devices. The firm is agnostic in terms of subsectors, indications and stage. Currently, the firm is active in many subsectors.

The firm seeks to acquire minority stakes in its portfolio companies. The firm is looking for companies with a talented and entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: